AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

Trump said he would announce pharmaceutical tariffs, as he increased tariffs on China to 125% and paused tariffs for 75 ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £153.18. The ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

FTSE 100 giants have been caught in the crosshairs of the US and China's escalating trade war leaving investors panicked.

Trump said overnight that the US would soon introduce a 'major tariff' on pharmaceuticals to force firms to relocate medicine production to America.

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...